151 related articles for article (PubMed ID: 33896321)
1. Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V; Husain M; Kirschner L; Shah MH; Konda B
Expert Opin Emerg Drugs; 2021 Jun; 26(2):165-178. PubMed ID: 33896321
[No Abstract] [Full Text] [Related]
2. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
3. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
4. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
Raj N; Zheng Y; Kelly V; Katz SS; Chou J; Do RKG; Capanu M; Zamarin D; Saltz LB; Ariyan CE; Untch BR; O'Reilly EM; Gopalan A; Berger MF; Olino K; Segal NH; Reidy-Lagunes DL
J Clin Oncol; 2020 Jan; 38(1):71-80. PubMed ID: 31644329
[TBL] [Abstract][Full Text] [Related]
6. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
Brabo EP; Moraes AB; Neto LV
J Endocrinol Invest; 2020 Nov; 43(11):1531-1542. PubMed ID: 32468513
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Tierney JF; Vogle A; Finnerty B; Zarnegar R; Ghai R; Gattuso P; Fahey TJ; Keutgen XM
J Surg Res; 2020 Dec; 256():90-95. PubMed ID: 32683062
[TBL] [Abstract][Full Text] [Related]
8. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey RT; Giger O; Seetho I; Marker A; Pitfield D; Boyle LH; Gurnell M; Shaw A; Tischkowitz M; Maher ER; Chatterjee VK; Janowitz T; Mells G; Corrie P; Challis BG
Semin Oncol; 2018 Jun; 45(3):151-155. PubMed ID: 30262398
[TBL] [Abstract][Full Text] [Related]
9. The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma.
Grisanti S; Cosentini D; Laganà M; Volta AD; Palumbo C; Massimo Tiberio GA; Sigala S; Berruti A
Future Oncol; 2020 Dec; 16(36):3017-3020. PubMed ID: 32857613
[No Abstract] [Full Text] [Related]
10. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
12. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.
Carneiro BA; Konda B; Costa RB; Costa RLB; Sagar V; Gursel DB; Kirschner LS; Chae YK; Abdulkadir SA; Rademaker A; Mahalingam D; Shah MH; Giles FJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6193-6200. PubMed ID: 31276163
[TBL] [Abstract][Full Text] [Related]
14. The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
[TBL] [Abstract][Full Text] [Related]
15. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
16. Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.
Pak C; Yoon S; Lee JL; Yun T; Park I
Curr Oncol Rep; 2024 Apr; 26(4):307-317. PubMed ID: 38381366
[TBL] [Abstract][Full Text] [Related]
17. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
[TBL] [Abstract][Full Text] [Related]
18. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.
Landwehr LS; Altieri B; Schreiner J; Sbiera I; Weigand I; Kroiss M; Fassnacht M; Sbiera S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474412
[TBL] [Abstract][Full Text] [Related]
19. Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment.
Araújo AN; Bugalho MJ
Horm Metab Res; 2021 May; 53(5):285-292. PubMed ID: 33962475
[TBL] [Abstract][Full Text] [Related]
20. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]